Acute Leukemia after Adjuvant Therapy of Gastrointestinal Cancer with Semustine (Methyl-CCNU)

Harvey E. Finkel; Fred Rosner; Hans W. Grünwald; John D. Boice; Mark H. Greene; John Y. Killen; Joseph F. Fraumeni

doi:10.1056/NEJM198404193101615

Acute Leukemia after Adjuvant Therapy of Gastrointestinal Cancer with Semustine (Methyl-CCNU)

Harvey E. Finkel, Fred Rosner, Hans W. Grünwald, John D. Boice, Mark H. Greene, John Y. Killen, Joseph F. Fraumeni

Research output: Contribution to journal › Letter › peer-review

Abstract

To the Editor: … Being statistically ignorant, and probably biased, I have trouble dealing with one statement in the paper by Boice et al. (Nov. 3 issue) — namely, that the “six-year cumulative mean risk … of acquiring a leukemic disorder after treatment with semustine was 4.0 … percent.”* There were 14 cases of leukemia or a related disorder among a total of 2067 patients treated with the drug, which I calculate as a total frequency of 0.68 percent for the duration of the period of observation. Are the authors really predicting that 4 percent of the.

Original language	English
Pages (from-to)	1057-1058
Number of pages	2
Journal	New England Journal of Medicine
Volume	310
Issue number	16
DOIs	https://doi.org/10.1056/NEJM198404193101615
State	Published - 19 Apr 1984
Externally published	Yes

Access to Document

10.1056/NEJM198404193101615

Cite this

@article{eecc1dc931a1413a8eaa0b14b2582be2,

title = "Acute Leukemia after Adjuvant Therapy of Gastrointestinal Cancer with Semustine (Methyl-CCNU)",

abstract = "To the Editor: … Being statistically ignorant, and probably biased, I have trouble dealing with one statement in the paper by Boice et al. (Nov. 3 issue) — namely, that the “six-year cumulative mean risk … of acquiring a leukemic disorder after treatment with semustine was 4.0 … percent.”* There were 14 cases of leukemia or a related disorder among a total of 2067 patients treated with the drug, which I calculate as a total frequency of 0.68 percent for the duration of the period of observation. Are the authors really predicting that 4 percent of the.",

author = "Finkel, \{Harvey E.\} and Fred Rosner and Gr{\"u}nwald, \{Hans W.\} and Boice, \{John D.\} and Greene, \{Mark H.\} and Killen, \{John Y.\} and Fraumeni, \{Joseph F.\}",

year = "1984",

month = apr,

day = "19",

doi = "10.1056/NEJM198404193101615",

language = "English",

volume = "310",

pages = "1057--1058",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Acute Leukemia after Adjuvant Therapy of Gastrointestinal Cancer with Semustine (Methyl-CCNU)

AU - Finkel, Harvey E.

AU - Rosner, Fred

AU - Grünwald, Hans W.

AU - Boice, John D.

AU - Greene, Mark H.

AU - Killen, John Y.

AU - Fraumeni, Joseph F.

PY - 1984/4/19

Y1 - 1984/4/19

N2 - To the Editor: … Being statistically ignorant, and probably biased, I have trouble dealing with one statement in the paper by Boice et al. (Nov. 3 issue) — namely, that the “six-year cumulative mean risk … of acquiring a leukemic disorder after treatment with semustine was 4.0 … percent.”* There were 14 cases of leukemia or a related disorder among a total of 2067 patients treated with the drug, which I calculate as a total frequency of 0.68 percent for the duration of the period of observation. Are the authors really predicting that 4 percent of the.

AB - To the Editor: … Being statistically ignorant, and probably biased, I have trouble dealing with one statement in the paper by Boice et al. (Nov. 3 issue) — namely, that the “six-year cumulative mean risk … of acquiring a leukemic disorder after treatment with semustine was 4.0 … percent.”* There were 14 cases of leukemia or a related disorder among a total of 2067 patients treated with the drug, which I calculate as a total frequency of 0.68 percent for the duration of the period of observation. Are the authors really predicting that 4 percent of the.

UR - https://www.scopus.com/pages/publications/0021176671

U2 - 10.1056/NEJM198404193101615

DO - 10.1056/NEJM198404193101615

M3 - Letter

C2 - 6708984

AN - SCOPUS:0021176671

SN - 0028-4793

VL - 310

SP - 1057

EP - 1058

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

Acute Leukemia after Adjuvant Therapy of Gastrointestinal Cancer with Semustine (Methyl-CCNU)

Abstract

Access to Document

Fingerprint

Cite this